ABSORPTION OF ORAL OFLOXACIN AFTER CYTOTOXIC CHEMOTHERAPY FOR HEMATOLOGICAL MALIGNANCY

被引:9
作者
BROWN, NM [1 ]
WHITE, LO [1 ]
BLUNDELL, EL [1 ]
CHOWN, SR [1 ]
SLADE, RR [1 ]
MACGOWAN, AP [1 ]
REEVES, DS [1 ]
机构
[1] SOUTHMEAD GEN HOSP,SOUTHMEAD HLTH SERV NHS TRUST,DEPT HAEMATOL,BRISTOL BS10 5NB,AVON,ENGLAND
关键词
D O I
10.1093/jac/32.1.117
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Ten patients with newly diagnosed haematological malignancy were given ofloxacin, 400 mg daily orally, for antibacterial prophylaxis during neutropenia. Before cyto-toxic chemotherapy was given, and on three occasions between days 2-3, 5-7 and 8-10 afterwards, blood samples were taken before and 1, 2, 3, 4, 6 and 10 h after administration of ofloxacin. Serum ofloxacin concentrations were measured by HPLC. Mean (range) pharmacokinetic parameters before chemotherapy were: Cmax, 6·1 (2·7-9·1) mg/L; AUC0-2, 7·5 (1·9-11·6) mg.h/L. On days 2-3 post-chemotherapy the values were reduced to: Cmax, 5·0 (3·6-7·3) mg/L; AUC0-2, 5·8 (1·9-7·8) mg.h/L. On days 5-7 the values were: Cmax, 6·1 (4·0-10·4) mg/L; AUC0-2, 8·5 (0·8-16·8) mg.h/L, and by days 8-10 the values were: Cmax, 6·4 (3·3-12·5) mg/L; AUC0-2, 8·6 (0·8-23·1) mg.h/L. There was a statistically significant difference between Cmax pre- and Cmax two to three days post-chemotherapy (paired t-test, P = 0·05). These changes are similar to those previously reported with ciprofloxacin but less marked. © 1993 The British Society for Antimicrobial Chemotherapy.
引用
收藏
页码:117 / 122
页数:6
相关论文
共 9 条
[1]   STREPTOCOCCAL AND ENTEROCOCCAL BACTEREMIA IN PATIENTS WITH CANCER [J].
AWADA, A ;
VANDERAUWERA, P ;
MEUNIER, F ;
DANEAU, D ;
KLASTERSKY, J .
CLINICAL INFECTIOUS DISEASES, 1992, 15 (01) :33-48
[2]  
GRUNEBERG RN, 1988, J ANTIMICROB CHEMOTH, V22, P9
[3]   REDUCED ABSORPTION OF ORAL CIPROFLOXACIN AFTER CHEMOTHERAPY FOR HEMATOLOGICAL MALIGNANCY [J].
JOHNSON, EJ ;
MACGOWAN, AP ;
POTTER, MN ;
STOCKLEY, RJ ;
WHITE, LO ;
SLADE, RR ;
REEVES, DS .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1990, 25 (05) :837-842
[4]   PHARMACOKINETICS OF OFLOXACIN AFTER PARENTERAL AND ORAL-ADMINISTRATION [J].
LODE, H ;
HOFFKEN, G ;
OLSCHEWSKI, P ;
SIEVERS, B ;
KIRCH, A ;
BORNER, K ;
KOEPPE, P .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1987, 31 (09) :1338-1342
[5]   ACUTE MYELOGENOUS LEUKEMIA - CURRENT TREATMENT AND FUTURE-DIRECTIONS [J].
MASTRIANNI, DM ;
TUNG, NM ;
TENEN, DG .
AMERICAN JOURNAL OF MEDICINE, 1992, 92 (03) :286-295
[6]   INTERACTIONS OF FLUOROQUINOLONES WITH OTHER DRUGS - MECHANISMS, VARIABILITY, CLINICAL-SIGNIFICANCE, AND MANAGEMENT [J].
RADANDT, JM ;
MARCHBANKS, CR ;
DUDLEY, MN .
CLINICAL INFECTIOUS DISEASES, 1992, 14 (01) :272-284
[7]   NEUTROPENIC ENTEROCOLITIS FOLLOWING TREATMENT WITH CYTOSINE ARABINOSIDE-CONTAINING REGIMENS FOR HEMATOLOGICAL MALIGNANCIES - A POTENTIATING ROLE FOR AMSACRINE [J].
VLASVELD, LT ;
ZWAAN, FE ;
FIBBE, WE ;
TJON, RTO ;
THAM, A ;
KLUIN, PM ;
WILLEMZE, R .
ANNALS OF HEMATOLOGY, 1991, 62 (04) :129-134
[8]   A PRELIMINARY-REPORT ON THE PHARMACOKINETICS OF OFLOXACIN, DESMETHYL OFLOXACIN AND OFLOXACIN N-OXIDE IN PATIENTS WITH CHRONIC RENAL-FAILURE [J].
WHITE, LO ;
MACGOWAN, AP ;
LOVERING, AM ;
REEVES, DS ;
MACKAY, IG .
DRUGS, 1987, 34 :56-61
[9]  
WISE R, 1986, J ANTIMICROBIAL C SD, V8, P71